Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial (European Urology Oncology)

This is the first study to examine androgen receptor inhibition with the addition of 6 mo of enzalutamide to standard salvage radiotherapy setting after radical prostatectomy. Our results show that addition of enzalutamide is safe and may improve prostate cancer remission rates at 2 and 3 yr.